A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 12 to Less Than 18 Years Old
Latest Information Update: 22 Jan 2026
At a glance
- Drugs Tenapanor (Primary)
- Indications Constipation; Irritable bowel syndrome
- Focus Registrational; Therapeutic Use
- Acronyms R-Ally
- Sponsors Ardelyx
Most Recent Events
- 12 Jan 2026 Planned End Date changed from 31 Dec 2025 to 1 Jun 2026.
- 12 Jan 2026 Planned primary completion date changed from 31 Dec 2025 to 1 Jun 2026.
- 06 May 2025 Results presented in an Ardelyx Media Release.